ONO and Seikagaku have signed a basic agreement related to co-development and marketing collaboration on Gel-One for the treatment of osteoarthritis in Japan

ONO和Seikagaku已就Gel-One在日本治疗骨关节炎的共同开发和营销合作签署了一项基本协议。

Gel-One is currently undergoing Phase III clinical studies and long-term safety study in Japan

Gel-One目前在日本正在进行III期临床研究和长期安全性研究。

Osaka, Japan, April 25, 2025 – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan, President and COO: Toichi Takino; ”ONO”) announced that it has entered into a basic agreement with Seikagaku Corporation (Tokyo, Japan, President and CEO: Ken Mizutani; “Seikagaku”) related to co-development and marketing collaboration on Gel-One under development by Seikagaku for the treatment of osteoarthritis in Japan.

日本大阪，2025年4月25日——小野药品工业株式会社（总部：日本大阪，总裁兼首席运营官：泷野藤一；“ONO”）宣布，已与生化学工业株式会社（东京，日本，总裁兼首席执行官：水谷健；“生化学”）就其正在开发的用于治疗日本骨关节炎的Gel-One达成共同开发和营销合作的基本协议。

The companies will further discuss to sign a definitive agreement on Gel-One..

公司将就Gel-One进一步商讨签署最终协议。

In Japan, three Phase III clinical studies are underway, a study for osteoarthritis of the knee, a study for osteoarthritis of the hip, and a long-term safety study for both joints. The companies are committed to facilitating these clinical studies as quickly as possible to obtain an approval for manufacturing and marketing authorization for the product at an earlier date..

在日本，有三项三期临床研究正在进行中，分别是针对膝关节骨关节炎的研究、髋关节骨关节炎的研究，以及针对这两种关节的长期安全性研究。这些公司致力于尽快推动这些临床研究，以便早日获得产品的生产和上市许可。

About Gel-One for the treatment of osteoarthritis

关于Gel-One治疗骨关节炎

Gel-One is an intra-articular injection whose main ingredient is a cross-linked hyaluronate, utilizing Seikagaku’s unique cross-linking technology. Since Gel-One remains in the joint for a long period of time, a single injection of Gel-One is expected to provide long-term pain relief. The product has been available in overseas markets since 2012 as Gel-one® (U.S.) and HyLink® (Taiwan and Italy) indicated for osteoarthritis of the knee.

Gel-One是一种关节内注射剂，其主要成分是交联透明质酸，采用了生化学独特的交联技术。由于Gel-One在关节内停留时间较长，因此单次注射即可提供长期的疼痛缓解。该产品自2012年起已在海外市场推出，品牌名为Gel-One®（美国）和HyLink®（台湾和意大利），适用于膝骨关节炎。

Additionally, whereas the indication for Gel-One in overseas markets is the knee joint, in Japan, Seikagaku will concurrently conduct a study of Gel-One for osteoarthritis of the hip alongside the knee study with the aim of expanding the target patient population..

此外，虽然Gel-One在海外市场的适应症是膝关节，但在日本，Seikagaku将同时进行Gel-One针对髋关节骨关节炎的研究，与膝关节研究并行，旨在扩大目标患者群体。